
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3437478/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pd (II) complexes bearing "SNS―pincerâ€ŧype thioether ligands: Application as catalysts in the synthesis of vitamin K ₃ . Applied Organometallic Chemistry, 2022, 36, e6467.	3.5	7
2	Endothelial Progenitor Cell Levels and Extent of Post-prandial Lipemic Response. Frontiers in Nutrition, 2022, 9, 822131.	3.7	1
3	Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology, 2022, 15, 97-106.	2.2	4
4	Çoklu İlaca Dirençli Akut Graft Versus Host Hastalığında Ruksolitinib. LLM Dergi, 2022, 6, 1−8.	0.0	0
5	Cytotoxic effects of water and ethanolic extracts of Turkish propolis on human laryngeal epidermoid carcinoma cell lines. Food and Health, 2022, 8, 218-228.	0.4	0
6	The assessment of the Long Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine. Turkish Journal of Haematology, 2021, 38, 306-313.	0.5	2
7	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. Turkish Journal of Medical Sciences, 2021, 51, 1033-1042.	0.9	0
8	Brentuximab vedotin consolidation therapy after autologous stemâ€cell transplantation in patients with highâ€risk Hodgkin lymphoma: Multicenter retrospective study. Hematological Oncology, 2021, 39, 498-505.	1.7	12
9	Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study. Turkish Journal of Haematology, 2021, 38, 101-110.	0.5	5
10	Diffüz Büyük B Hücreli Lenfomada Prognostik Skorlama Sistemlerinin Karşılaştırılması. LLM D 27-33.	ergi, 2021	1,5,
11	Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis. American Journal of Blood Research, 2021, 11, 279-285.	0.6	0
12	Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective. Turkish Journal of Haematology, 2021, 38, 344-346.	0.5	0
13	An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy. Blood, 2021, 138, 4730-4730.	1.4	0
14	<i>Rosa canina</i> Extract has Antiproliferative and Proapoptotic Effects on Human Lung and Prostate Cancer Cells. Nutrition and Cancer, 2020, 72, 273-282.	2.0	19
15	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e474-e484.	0.4	7
16	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology, 2020, 99, 2565-2576.	1.8	19
17	Ekstranodal Diffüz Büyük B Hücreli Lenfomada Bcl-2 ve Myc Ekspresyon Birlikteliğinin Tedavi Yanıtı Prognoza Etkisinin Geriye Dönük Olarak Değerlendirilmesi. LLM Dergi, 2020, 3, 92-100.	ve 0.0	0
18	High levels of endothelial progenitor cells and circulating endothelial cells in patients with Behçet's disease and their relationship to disease activity. Anais Brasileiros De Dermatologia, 2019, 94, 320-326.	1.1	7

#	Article	IF	CITATIONS
19	Synthesis of novel chiral metal complexes derived from chiral thiosemicarbazide ligands as potential antioxidant agents. Chirality, 2019, 31, 434-444.	2.6	10
20	The Turkish experience with therapeutic plasma exchange: A national survey. Transfusion and Apheresis Science, 2019, 58, 287-292.	1.0	6
21	Synthesis of Fe and Cu metal complexes derived from â€~SNS' Pincer type ligands and their efficient catalyst precursors for the chemical fixation of \$\$hbox {CO}_{2}\$\$ CO 2. Journal of Chemical Sciences, 2019, 131, 1.	1.5	14
22	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. Turkish Journal of Haematology, 2019, 36, 230-237.	0.5	8
23	Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study. Blood, 2019, 134, 5476-5476.	1.4	Ο
24	Higher Thrombin-Antithrombin III Complex Levels May Indicate Severe Acute Pancreatitis. Digestive Diseases, 2018, 36, 244-251.	1.9	5
25	Repression of oxidative phosphorylation sensitizes leukemia cell lines to cytarabine. Hematology, 2018, 23, 330-336.	1.5	7
26	Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia. Central-European Journal of Immunology, 2018, 43, 276-280.	1.2	5
27	Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study. Chemotherapy, 2018, 63, 207-213.	1.6	11
28	Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology, 2018, 23, 771-777.	1.5	5
29	Circulating parameters of oxidative stress and hypoxia in normal pregnancy and HELLP syndrome. Advances in Clinical and Experimental Medicine, 2018, 27, 1567-1572.	1.4	10
30	Long-term Treatment Outcome of Patients with Hairy Cell Leukemia: A Single-Center Experience. Turkiye Klinikleri Journal of Medical Sciences, 2018, 38, 236-240.	0.1	0
31	Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia. Journal of the National Medical Association, 2017, 109, 23-27.	0.8	20
32	Role of platelets in immune system and inflammation. Porto Biomedical Journal, 2017, 2, 311-314.	1.0	68
33	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Oncology, 2017, 28, 2496-2502.	1.2	60
34	The importance of risk factors for the prediction of patients with invasive pulmonary aspergillosis. Revista Da Associação Médica Brasileira, 2017, 63, 764-770.	0.7	6
35	Autoantibodies against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Haematology, 2017, 34, 307-313.	0.5	4
36	The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia. Turkish Journal of Haematology, 2016, 33, 135-140.	0.5	10

#	Article	IF	CITATIONS
37	The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene, 2016, 586, 263-267.	2.2	5
38	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2016, 17, 1851-1858.	1.8	6
39	The indicator of hypoxia in acute leukemia: Ischemia-modified albumin. Cancer Biomarkers, 2015, 15, 559-565.	1.7	6
40	Poststreptococcal Glomerulonephritis in a Patient with Essential Thrombocytosis. Journal of Nippon Medical School, 2015, 82, 59-63.	0.9	0
41	Anti-carbonic anhydrase antibodies in iron deficiency anemia. Hematology, 2015, 20, 363-367.	1.5	4
42	Raoultella ornithinolytica causing fatal sepsis. Brazilian Journal of Infectious Diseases, 2015, 19, 230-231.	0.6	16
43	Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4). Turkish Journal of Haematology, 2015, 32, 100-117.	0.5	6
44	The Effect of Dexmedetomidine on Oxidative Stress during Pneumoperitoneum. BioMed Research International, 2014, 2014, 1-5.	1.9	16
45	Aggressive Multiple Myeloma with Unusual Morphology. Turkish Journal of Haematology, 2014, 31, 437-438.	0.5	0
46	C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease. Hematology, 2014, 19, 213-216.	1.5	7
47	The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. International Journal of Infectious Diseases, 2013, 17, e1056-e1059.	3.3	269
48	Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels. Clinical and Experimental Hypertension, 2013, 35, 134-140.	1.3	7
49	Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells. Cytotherapy, 2013, 15, 352-361.	0.7	13
50	Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia. Wspolczesna Onkologia, 2013, 1, 83-87.	1.4	1
51	Is SCUBE 1 a new biomarker for gastric cancer?. Cancer Biomarkers, 2012, 11, 191-195.	1.7	23
52	HLA-DRB1 allele distribution and its relation to rheumatoid arthritis in eastern Black Sea Turkish population. Rheumatology International, 2012, 32, 1003-1007.	3.0	27
53	Associations of HLAâ€DRB1 alleles with antiâ€eitrullinated protein antibodyâ€positive and antiâ€eitrullinated protein antibodyâ€positive and antiâ€eitrullinated protein antibodyâ€negative rheumatoid arthritis in northern east part of Turkey. International Journal of Rheumatic Diseases, 2012, 15, 538-545.	1.9	6
54	Relation of HLA-A, -B, -DRB1 Alleles and Haplotypes in Patients with Acute Leukemia: A Case Control Study. Archives of Medical Research, 2011, 42, 305-310.	3.3	12

#	Article	IF	CITATIONS
55	MTHFR C677T Polymorphism and Its Relationship to Myocardial Infarction in the Eastern Black Sea Region of Turkey. Archives of Medical Research, 2011, 42, 709-712.	3.3	13
56	Effect of Early or Delayed Administration of Warfarin with Heparin on Thrombosis in Pulmonary Thromboembolism. Medical Principles and Practice, 2011, 20, 181-186.	2.4	7
57	Multiple myeloma with multilobated plasma cell nuclei. Turkish Journal of Haematology, 2011, 28, 158-159.	0.5	4
58	The Role of Fibrinolytic and Antifibrinolytic Activities in the Pathophysiology of HELLP Syndrome. Hypertension in Pregnancy, 2011, 30, 275-286.	1.1	6
59	The use of Ankaferd blood stopper in a patient with Glanzmann's thrombasthenia with gingival bleeding. Blood Coagulation and Fibrinolysis, 2010, 21, 382-383.	1.0	15
60	Familial Hodgkin's Lymphoma from the Perspective of HLA. Internal Medicine, 2010, 49, 607-610.	0.7	6
61	A Case of Acute Colitis with Severe Rectal Bleeding in a Patient with Chronic Myeloid Leukemia after Dasatinib Use. Acta Haematologica, 2010, 123, 205-206.	1.4	50
62	FDG-PET in mantle cell lymphoma involving skin. Turkish Journal of Haematology, 2010, 27, 324-5.	0.5	1
63	The changes in complete blood count in thyroid cancer patients treated with radioactive iodine ablation therapy. Turkish Journal of Haematology, 2010, 27, 269-274.	0.5	4
64	The expression of LMO2 protein in acute B-cell and myeloid leukemia. Hematology, 2010, 15, 132-134.	1.5	10
65	Can ischemia-modified albumin be a valuable indicator of tissue ischemia in polycythemia vera?. Hematology, 2010, 15, 151-156.	1.5	5
66	Treatment related changes in antifibrinolytic activity in patients with polycythemia vera. Hematology, 2010, 15, 391-396.	1.5	12
67	Treatment of tumor lysis syndrome with the highest known uric acid level. Renal Failure, 2010, 32, 895-898.	2.1	4
68	A Rare Plasma Cell Dyscrasias: IgM Myeloma: Case Report. Turkiye Klinikleri Journal of Medical Sciences, 2010, 30, 1727-1731.	0.1	0
69	Association of Gastrointestinal Stromal Tumor and Acute Myeloid Leukemia Preceded by Myelodysplastic Syndrome with Refractory Anemia. Tumori, 2009, 95, 240-242.	1.1	4
70	Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate. Hematology, 2009, 14, 220-223.	1.5	5
71	Can a high platelet count be responsible for diabetes insipidus in acute myelogenous leukemia with monosomy 7 and inversion 3 (q21q26)?. International Journal of Hematology, 2009, 90, 273-274.	1.6	6
72	The association of bladder myeloid sarcoma and unclassified myelodysplastic/myeloproliferative disease. Turkish Journal of Haematology, 2009, 26, 90-2.	0.5	1

#	Article	IF	CITATIONS
73	Breakthrough Trichosporon asahii Fungemia in Neutropenic Patient with Acute Leukemia while Receiving Caspofungin. Infection, 2008, 36, 68-70.	4.7	63
74	Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 91-92.	1.5	11
75	Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 329-330.	1.5	6
76	Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. Journal of Experimental and Clinical Cancer Research, 2008, 27, 11.	8.6	64
77	Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever. Journal of Clinical Virology, 2008, 42, 415-417.	3.1	26
78	Change of coagulation parameters after double plateletpheresis. Transfusion and Apheresis Science, 2007, 37, 161-163.	1.0	11
79	The Relation of Lymphomaand Hepatitis B Virus/Hepatitis C Virus Infections in the Region of East Black Sea, Turkey. Tumori, 2007, 93, 536-539.	1.1	19
80	Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever. Journal of Infection, 2007, 55, 184-187.	3.3	16
81	The role of hepatocyte growth factor in the differentiation of dendritic cells from peripheral blood monocytes. Journal of King Abdulaziz University, Islamic Economics, 2007, 28, 688-95.	1.1	1
82	The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. Tumori, 2007, 93, 536-9.	1.1	10
83	Effects of Interferon-α-2a on Th3 Cytokine Response in Multiple Myeloma Patients. Tumori, 2004, 90, 387-389.	1.1	3
84	MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. American Journal of Hematology, 2004, 76, 40-43.	4.1	21
85	Crimean-Congo Hemorrhagic Fever in Turkey. Emerging Infectious Diseases, 2004, 10, 1379-1384.	4.3	229
86	Effects of interferon-alpha-2a on Th3 cytokine response in multiple myeloma patients. Tumori, 2004, 90, 387-9.	1.1	2
87	Effect of High-Dose Medroxyprogesterone Acetate on Tumor Necrosis Factor-Alpha Release in Patients with Chemotherapy-Induced Neutropenia. Journal of Chemotherapy, 1997, 9, 377-381.	1.5	0
88	Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. International Journal of Hematologic Oncology, 0, , .	1.6	0